EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Tight Junction Proteins as Therapeutic Targets to Treat Liver Fibrosis and Hepatocellular Carcinoma

Antonio Saviano, Natascha Roehlen, Thomas F Baumert

Seminars in Liver Disease · 01.05.2024 · 44 (02) · 180-190

DOI: 10.1055/s-0044-1785646 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Seminars in Liver Disease, erschienen am 01.05.2024. Verfasst von Antonio Saviano und 2 weiteren Autor:innen. Beteiligte Einrichtung: Inserm, U1110, Institute of Translational Medicine and Liver Disease, Strasbourg, France. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Liver Cirrhosis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 105 Literaturangaben. Gefördert von: European Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the last decade tight junction proteins exposed at the surface of liver or cancer cells have been uncovered as mediators of liver disease biology: Claudin-1 and Occludin are host factors for hepatitis C virus entry and Claudin-1 has been identified as a driver for liver fibrosis and hepatocellular carcinoma (HCC). Moreover, Claudins have emerged as therapeutic targets for liver disease and HCC. CLDN1 expression is upregulated in liver fibrosis and HCC. Monoclonal antibodies (mAbs) targeting Claudin-1 have completed preclinical proof-of-concept studies for treatment of liver fibrosis and HCC and are currently in clinical development for advanced liver fibrosis. Claudin-6 overexpression is associated with an HCC aggressive phenotype and treatment resistance. Claudin-6 mAbs or chimeric antigen receptor-T cells therapies are currently being clinically investigated for Claudin-6 overexpressing tumors. In conclusion, targeting Claudin proteins offers a novel clinical opportunity for the treatment of patients with advanced liver fibrosis and HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsLiver CirrhosisHumansAnimalsTight Junction ProteinsMolecular Targeted TherapyClaudinsAntineoplastic Agents, ImmunologicalTight Junctions

Substanzen

Tight Junction ProteinsClaudinsAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Inserm, U1110, Institute of Translational Medicine and Liver Disease, Strasbourg, France.
  • University of Strasbourg, Strasbourg, France.
  • Service d'hépato-gastroentérologie, Pôle Hépato-digestif, Institut-Hospitalo-Universitaire, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
  • Department of Medicine II, Gastroenterology, Hepatology, Endocrinology and Infectious Diseases, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Berta-Ottenstein-Programme, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Institut Universitaire de France, Paris, France.

Förderung

  • European Research Council

Zitieren

APA

Saviano, A., Roehlen, N., & Baumert, T. F. (2024). Tight Junction Proteins as Therapeutic Targets to Treat Liver Fibrosis and Hepatocellular Carcinoma. Seminars in Liver Disease, 44(02), 180-190. https://doi.org/10.1055/s-0044-1785646

Vancouver

Saviano A, Roehlen N, Baumert TF. Tight Junction Proteins as Therapeutic Targets to Treat Liver Fibrosis and Hepatocellular Carcinoma. Seminars in Liver Disease. 2024;44(02):180-190. doi:10.1055/s-0044-1785646

BibTeX
@article{Saviano2024,
  author = {Saviano, Antonio and Roehlen, Natascha and Baumert, Thomas F},
  title = {Tight Junction Proteins as Therapeutic Targets to Treat Liver Fibrosis and Hepatocellular Carcinoma},
  journal = {Seminars in Liver Disease},
  year = {2024},
  volume = {44},
  number = {02},
  pages = {180--190},
  doi = {10.1055/s-0044-1785646}
}
Kostenlos starten →